Novabay pharmaceuticals and eyenovia to co-promote prescription ophthalmic products to u.s. eyecare professionals

Emeryville, calif. and new york, march 13, 2024 (globe newswire) -- novabay pharmaceuticals, inc. (nyse american: nby) and eyenovia, inc. (nasdaq: eyen) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the u.s. under the agreement, novabay will market eyenovia's clobetasol propionate ophthalmic suspension 0.05% (“clobetasol”), a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its u.s. physician-dispensed channel. eyenovia will market novabay's prescription avenova® antimicrobial lid & lash solution through its mydcombi and clobetasol sales representatives strategically located across the u.s.
EYEN Ratings Summary
EYEN Quant Ranking